Brief: Moberg Pharma Expects National Approvals For New Onychomycosis Treatment

Moberg Pharma AB (publ)

03/08/2023 08:23

Aug 3 (Reuters) - Moberg Pharma AB (publ)  MBPH.ST :
    * APPROVAL IN EUROPEAN UNION REPRESENTS FIRST MARKETING
AUTHORIZATIONS FOR OUR NEW ONYCHOMYCOSIS TREATMENT WORLDWIDE
    * NATIONAL APPROVALS ARE EXPECTED TO FOLLOW DURING UPCOMING
MONTHS
AND TIMELINES MAY VARY BETWEEN COUNTRIES
    * IN CONNECTION WITH APPROVAL, IT WAS FOUND THAT ONLY ONE OF
OUR
TWO SUPPLIERS OF ACTIVE SUBSTANCE TERBINAFINE WAS APPROVED
    * SHORT TERM WE THEREFORE HAVE A LIMITED SUPPLY OF
TERBINAFINE AND
ROLLOUT WILL BE A TWO-STEP PROCESS
    * LAUNCH IN TWO STAGES MEANS THAT SIGNIFICANT EXPECTED
REVENUES
ARE POSTPONED AND BOD HAS THEREFORE RESOLVED ON A RIGHTS ISSUE
OF ABOUT SEK 100 MLN

Source text for Eikon:  ID:nWkr7T5jTq 
Further company coverage:  MBPH.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))